SGN CD352A

Drug Profile

SGN CD352A

Alternative Names: SGN-CD352A

Latest Information Update: 28 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Developer Ligand Pharmaceuticals; Seattle Genetics
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT02954796)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top